Cargando…
Incidence of Secondary Bacterial Infections Following Utilization of Tocilizumab for the Treatment of COVID-19 – A Matched Retrospective Cohort Study
INTRODUCTION: Immunosuppressive agents are theorized to target the cytokine storm syndrome in COVID-19. However, the downstream effects regarding susceptibilities to secondary infection risk remains unknown. This study seeks to determine risk differences for secondary infections among COVID-19 patie...
Autores principales: | Moore, Joanna L., Stroever, Stephanie J., Rondain, Patricia E., Scatena, Robyn N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213077/ https://www.ncbi.nlm.nih.gov/pubmed/34194172 http://dx.doi.org/10.4103/jgid.jgid_358_20 |
Ejemplares similares
-
Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2022) -
Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2022) -
Medication Use Among Patients With COVID‐19 in a Large, National Dataset: Cerner Real‐World Data™
por: Stroever, Stephanie J., et al.
Publicado: (2021) -
Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis
por: Ignatius, Elisa H, et al.
Publicado: (2020) -
Matched cohort study on the efficacy of tocilizumab in patients with COVID-19
por: Rodríguez-Molinero, Alejandro, et al.
Publicado: (2021)